Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults

Clinical Infectious Diseases

Volumn 37, Issue 11, 2003, Pages 1405-1433

  Mandell, Lionel A ^a,g   Bartlett, John G ^b   Dowell, Scott F ^c   File Jr , Thomas M ^d   Musher, Daniel M ^e   Whitney, Cynthia ^c,f  

^a MCMASTER UNIVERSITY   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d SUMMA HEALTH SYSTEM   (United States)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Infectious Diseases Society   (United States)

^g HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; UNINDEXED DRUG;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BIOLOGICAL WARFARE; CHLAMYDOPHILA PNEUMONIAE; COMORBIDITY; DRUG TOLERABILITY; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOCOMPETENCE; INFLUENZA; LEGIONNAIRE DISEASE; MEDICAL DECISION MAKING; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; STREPTOCOCCUS PNEUMONIA; TREATMENT PLANNING;

ADULT; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BIOTERRORISM; CEFOTAXIME; CEFTRIAXONE; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; LEGIONNAIRES' DISEASE; MACROLIDES; MICROBIAL SENSITIVITY TESTS; PNEUMONIA; PNEUMONIA, PNEUMOCOCCAL; SEVERE ACUTE RESPIRATORY SYNDROME; STREPTOCOCCUS PNEUMONIAE;

EID: 0345550450     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/380488     Document Type: Review

References (235)

1. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. Infectious Diseases Society of America. Clin Infect Dis 1998; 26:811-38.
2. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-82.
3. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003; 138:109-18.
4. Halm EA, Teirstein AS. Management of community-acquired pneumonia. N Engl J Med 2002; 347:2039-45.
5. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31:383-421.
6. American College of Emergency Physicians. Clinical policy for the management and risk stratifications of community acquired pneumonia in adults in the emergency department. Ann Emerg Med 2001; 38:107-13.
7. Fine MJ, Yealy DM, Auble TE, et al. Translating the pneumonia severity index into practice: a trial to influence the admission decision. J Gen Intern Med 2002; 17(Suppl 1):192.
8. Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcome in patients with pneumonia. Arch Intern Med 2002; 162:1278-84.
9. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33:492-503.
10. Domínguez J, Galí N, Blanco S, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001; 119:243-9.
11. Burel E, Dufour P, Gauduchon V, Jarraud S, Etienne J. Evaluation of a rapid immunochromatographic assay for detection of Streptococcus pneumoniae antigen in urine samples. Eur J Clin Microbiol Infect Dis 2001; 20:840-1.
12. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001; 39:3495-8.
13. Farina C, Arosio M, Vailati F, Moioli F, Goglio A. Urinary detection of Streptococcus pneumoniae antigen for diagnosis of pneumonia. New Microbiol 2002; 25:259-63.
14. Yu VL, Kellog JA, Plouffe JF, et al. Evaluation of the Binax urinary, Gram stain and sputum culture for Streptococcus pneumoniae in patients with community-acquired pneumonia [abstract 262]. In: Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans). Alexandria, VA: Infectious Diseases Society of America, 2000.
15. Gutierrez F, Rodriguez JC, Ayelo A, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36:286-92.
16. Fadan H, Heimerl M, Varma C, Goodman G, Winkelstein P. Urinary excretion of pneumococcal cell wall polysaccharide in children. Pediatr Infect Dis J 2002; 21:791-3.
17. Adegbola RA, Obaro SK, Biney E, Greenwood BM. Evaluation of Binax NOW Streptococcus pneumoniae urinary antigen test in children in a community with a high carriage rate of pneumococcus. Pediatr Infect Dis J 2001; 20:718-9.
18. Dowell SF, Garman RL, Liu G, Levine O, Yang Y-H. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin Infect Dis 2001; 32:824-5.
19. Pesola GR. The urinary antigen test for the diagnosis of pneumococcal pneumonia. Chest 2001; 119:9-11.
20. Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to beta lactam antibiotics. Arch Intern Med 2001; 161:2538-44.
21. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J 1995; 14:885-90.
22. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-80.
23. Choi EH, Lee HJ. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis 1998; 26:1346-54.
24. Turret G, Blum S, Fazal B, Justman J, Telzak E. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high HIV seroprevalence. Clin Infect Dis 1999; 29: 321-7.
25. Feikin D, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223-9.
26. Heffelfinger JD, Dowel SF, Jorgensen JH, et al. Management of community acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160:1399-408.
27. World Health Organization (WHO). Cumulative number of reported probable cases of severe acute respiratory syndrome (SARS). Geneva: WHO, 2003.
28. Outbreak of severe acute respiratory syndrome - worldwide, 2003. JAMA 2003; 289:1775-6.
29. Update: outbreak of severe acute respiratory syndrome - worldwide, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:241-6, 248.
30. Outbreak of severe acute respiratory syndrome - worldwide, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:226-8.
31. Cluster of severe acute respiratory syndrome cases among protected health-care workers - Toronto, Canada, April 2003. MMWR Morb Mortal Wkly Rep 2003; 52:433-6.
32. Centers for Disease Control and Prevention. Interim domestic guidance on the use of respirators to prevent transmission of SARS. 6 May 2003. Available at: http://www.cdc.gov. Accessed on: 23 October 2003.
33. Ksiazek TG, Erdman D, Goldsmith C, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348:1953-66.
34. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348:1967-76.
35. Fouchier RA, Kuiken T, Schutten M, et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 2003; 423:240.
36. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300:1394-9.
37. Centers for Disease Control and Prevention. Updated interim US case definition of severe acute respiratory syndrome (SARS). 18 July 2003. Available at: http://www.cdc.gov/ncidod/sars/casedefinition/htm. Accessed on: 23 October 2003.
38. Updated interim surveillance case definition for severe acute respiratory syndrome (SARS) April 29, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:391-3.
39. World Health Organization. Case definitions for surveillance of severe acute respiratory syndrome (SARS). 1 May 2003. Available at: http: //www.who.int/csr/sars/casedefinition/en. Accessed on: 23 October 2003.
40. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361:1767-72.
41. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1977-85.
42. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348:1995-2005.
43. Wong KT, Antonio GE, Hui DS, et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 2003; 228:401-6.
44. Centers for Disease Control and Prevention. Severe acute respiratory syndrome (SARS) diagnosis/evaluation. 18 July 2003. http:// www.cdc.gov/ncidod/ sars/diagnosis.htm. Accessed on: 23 October 2003.
45. Severe acute respiratory syndrome (SARS) and coronavirus testing -United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52: 297-302.
46. Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159: 2576-80.
47. Gleason PP, Meehan TP, Fine JM, et al. Association between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159:2562-72.
48. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107(Suppl):34S-43S.
49. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-42.
50. Martinez JA, Horcajada JP, Almeld M, et al. Addition of a macrolide to a β-lactam based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:396-8.
51. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429:209-29.
52. File TM, Mandell LA. What is optimal antimicrobial therapy for bacterial pneumococcal pneumonia. Clin Infect Dis 2003; 36: 396-8.
53. Marston BJ, Plouffe JF, File TM, et al. Incidence of community acquired pneumonia requiring hospitalizations: results of a population-based active surveillance study in Ohio. Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997; 157: 1709-18.
54. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community acquired pneumonia with implications for therapy: a prospective Multicenter study of 359 cases. Medicine (Baltimore) 1990; 69:307-16.
55. Mundy LM, Auwaerter PG, Oldach D, et al. Community acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995; 152:1309-15.
56. Keller DW, Lipman HB, Marston BJ, et al. Clinical diagnosis of legionnaires' disease (LD) using a multivariate model [abstract K55]. In: Program and abstracts of the 35th Interscience on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:297.
57. Stout JE, Yu VL. Legionellosis. N Engl J Med 1997; 337:682-7.
58. Marston BJ, Lipman HB, Breiman RF. Surveillance for legionnaires' disease: risk factors for morbidity and mortality. Arch Intern Med 1994; 154:2417-22.
59. Benin AL, Benson RF, Arnold KE, et al. An outbreak of travel-associated legionnaires disease and Pontiac fever: the need for enhanced surveillance of travel-associated legionellosis in the United States. J Infect Dis 2002; 185:237-43.
60. Helbig JH, Uldum SA, Bernander S, et al. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial legionnaires' disease. J Clin Microbiol 2003; 41:838-40.
61. Den Boer JW, Yzerman EP, Schellekens J, et al: A large outbreak of Legionnaires' disease at a flower show, the Netherlands, 1999. Emerg Infect Dis 2002;8:37-43.
62. Vergis EN, Yu VL. New directions for future studies of community-acquired pneumonia: optimizing impact on patient care. Eur J Clin Microbiol Infect Dis 1999; 18:847-51.
63. Roig J, Aguilar X, Ruiz J, et al. Comparative study of Legionella pneumophila and other nosocomial-acquired pneumonias. Chest 1991; 99:344-50.
64. Sopena N, Sabria-Leal M, Pedro-Botet ML, et al. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. Chest 1998; 113:1195-200.
65. Gupta SK, Imperiale TF, Sarosi GA. Evaluation of the Winthrop-University Hospital criteria to identify Legionella pneumonia. Chest 2001; 120:1064-71.
66. Murdoch DR. Diagnosis of Legionella infection. Clin Infect Dis 2003; 36:64-9.
67. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Morb Mortal Wkly Rep 1997; 46(RR-10):1-55.
68. Roig J, Rello J, Yu VL. Legionnaires' disease: a rational approach to therapy. J Antimicrob Chemother 2003; 51:1119-29.
69. Edelstein PH. Antimicrobial chemotherapy for Legionnaires disease: time for a change. Ann Intern Med 1998; 129:328-30.
70. Heath CH, Grove DI, Looke DFM. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis 1996; 15:286-90.
71. Glezen WP, Greenberg SB, Atmar RL, et al. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000; 283:499-505.
72. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86.
73. Stockton J, Stephenson I, Fleming D, Zambon M. Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg Infect Dis 2002; 8:897-901.
74. Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis 2003; 187:785-90.
75. Greenberg SB. Viral pneumonia. Infect Dis Clin North Am 1991; 5: 603-21.
76. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56:296-301.
77. Kaiser L, Briones MS, Hayden FG. Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J Clin Virol 1999; 14:191-7.
78. Bellei N, Benfica D, Perosa AH, et al. Evaluation of a rapid test (QuickVue) compared with the shell vial assay for detection of influenza virus clearance after antiviral treatment. J Virol Methods 2003; 109:85-8.
79. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160:3243-7.
80. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355:827-35.
81. Gubareva LV, Kaiser L, Matrosovich MN, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183:523-31.
82. Kaiser L, Keene ON, Hammond JM, et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160:3234-40.
83. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-24.
84. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240-6.
85. Kaiser L, Hayden FG. Hospitalizing influenza in adults. Curr Clin Top Infect Dis 1999; 19:112-34.
86. Oliveira EC, Marik PE, Colice G. Influenza pneumonia: a descriptive study. Chest 2001; 119:1717-23.
87. Haake DA, Zakowski PC, Haake DL, Bryson YJ. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis 1990; 12: 788-98.
88. Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for Hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther 1999; 4:211-9.
89. Chapman LE, Ellis BA, Koster FT, et al. Discriminators between Hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive Hantavirus pulmonary syndrome. Clin Infect Dis 2002; 34:293-304.
90. Henderson DA. The looming threat of bioterrorism. Science 1999; 283:1279.
91. Eitzen E, Pavlin J, Cieslak T, et al., eds. Medical management of biological casualties handbook. 3rd ed. Frederick, MD: US Army Medical Research Institute of Infectious Diseases, 1998:15-21, 40-51.
92. Bartlett JG, Inglesby TV Jr, Borio L. Management of anthrax. Clin Infect Dis 2002; 35:851-8.
93. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933-44.
94. Kuehnert MJ, Doyle TJ, Hill HA, et al. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis 2003; 36:328-36.
95. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287:2236-52.
96. Tularemia - United States, 1990-2000. MMWR Morb Mortal Wkly Rep 2002; 51:181-4.
97. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001; 285:2763-73.
98. Shapiro DS, Schwartz DR. Exposure of laboratory workers to Francisella tularensis despite a bioterrorism procedure. J Clin Microbiol 2002; 40:2278-81.
99. Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994; 19:42-7.
100. Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore) 1985; 64: 251-69.
101. Mason WL, Eigelsbach HT, Little SF, Bates JH. Treatment of tularemia, including pulmonary tularemia, with gentamicin. Am Rev Respir Dis 1980; 121:39-45.
102. Limaye AP, Hooper CJ. Treatment of tularemia with fluoroquinolones: two cases and review. Clin Infect Dis 1999; 29:922-4.
103. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000; 283:2281-90.
104. Fatal human plague - Arizona and Colorado, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:617-20.
105. Rasoamanana B, Coulanges P, Michel P, Rasolofonirina N. Sensitivity of Yersinia pestis to antibiotics: 277 strains isolated in Madagascar between 1926 and 1989. Arch Inst Pasteur Madagascar 1989; 56:37-53.
106. Bonacorsi SP, Scavizzi MR, Guiyoule A, et al. Assessment of a fluoroquinolone, three beta lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection. Antimicrob Agents Chemother 1994; 38:481-6.
107. Russell P, Eley SM, Green M, et al. Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. J Antimicrob Chemother 1998; 41:301-5.
108. Pneumonia and influenza death rates, United States, 1979-1994. MMWR Morb Mortal Wkly Rep 1995; 44:535-7.
109. Muder R. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Am J Med 1998; 105:319-30.
110. Joikinen C, Heiskanem L, Juvonen H, et al. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in Eastern Finland. Clin Infect Dis 2001; 32:1141-54.
111. Ruiz M, Ewig S, Marcos M, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Resp Crit Care Med 1999; 160:397-405.
112. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994; 96:313-20.
113. Loeb M, McGeer A, McArthur M, Walter S, Simor AE. Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities. Arch Intern Med 1999; 159: 2058-64.
114. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157:1453-9.
115. Marrie TJ, Haldane EV, Faulkner RS, et al. Community-acquired pneumonia requiring hospitalization: is it different in the elderly? J Am Geriatr Soc 1985; 33:671-80.
116. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123:518-27.
117. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322-32.
118. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of healthcare workers in long-term care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175:1-6.
119. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of healthcare workers on mortality of elderly people in long term care: a randomized controlled trial. Lancet 2000; 355:93-7.
120. Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103:281-90.
121. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315:1318-27.
122. Örtqvist Å, Hedlund J, Burman LÅ, et al. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-age and elderly people. Lancet 1998; 351: 399-403.
123. Musher DM, Mediwala R, Phan HM, Chen G, Baughn RE. Nonspecificity of assaying for IgG to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia. Clin Infect Dis 2001; 32:534-8.
124. Kaufman P. Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharide; results of a six year study. Arch Intern Med 1947; 79:518-31.
125. Gaillat J, Zmirou D, Mallaret MR, et al. Essai clinique du vaccin antipneumococcique chez des personnes âgées vivant en institution. Rev Epidémiol Santé Publique 1985; 33:437-44.
126. Butler JC, Freiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Polysaccharide pneumococcal vaccine efficacy: an evaluation of current recommendations. JAMA 1993; 270:1826-31.
127. Sims RV, Steinmann WC, McConville JH, King LR, Zwich WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108:653-7.
128. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60.
129. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study. Arch Intern Med 1995; 155:2336-40.
130. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. New Engl J Med 2003; 348: 1747-55.
131. Whitney CG, Farley MM, Hader J, et al. Decline in invasive pneumococcal disease following the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46.
132. Centers for Disease Control and Prevention. Facilitating influenza and pneumococcal vaccination through standing orders programs. MMWR Morb Mortal Wkly Rep 2003; 52:68-9.
133. Bridges CB, Harper SA, Fukuda K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003; 52(RR-8): 1-34.
134. Harper SA, Fukuda K, Cox J, Bridges CB. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52(RR-13): 1-8.
135. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46:1-24.
136. Sisk JE, Whang W, Butler JC, Sneller V-P, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003; 138:960-8.
137. Lynch JP, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002; 34(Suppl):S27-46.
138. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002; 34(Suppl 1):S4-S16.
139. Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286:1857-62.
140. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45:1721-9.
141. Corso A, Severina EP, Petruk VF, Mauriz YR, Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae: isolates causing respiratory disease in the United States. Microb Drug Resist 1998; 4:325-37.
142. Shortridge V, Doern G, Brueggeman A, Beyer J, Flamm R. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in The United States in 1994-1995. Clin Infect Dis 1999; 29: 1186-8.
143. Tait-Kamradt A, Davies T, Appelbaum PC, et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44:3395-401.
144. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. New Engl J Med 2002; 346:630-1.
145. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis 2003; 9:432-7.
146. Gay K, Baughman W, Miller Y, et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population based assessment. J Infect Dis 2000; 182:1417-24.
147. Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C, et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45:3334-40.
148. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(Suppl 2):S81-93.
149. Dixon JMS. Pneumococcus resistant to erythromycin and lincomycin. Lancet 1967; 1:573.
150. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000; 31:613-5.
151. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31:1008-11.
152. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35:556-64.
153. Bertho G, Gharbi-Benarous J, Delaforge M, et al. Conformational analysis of ketolide, conformations of RU 004 in solution and bound to bacterial ribosomes. J Med Chem 1998; 27:3373-86.
154. Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999; 31:623-31.
155. Leclercq R. Will resistance to ketolides develop in Streptococcus pneumoniae? Antimicrob Agents Chemother 2002; 46:2727-34.
156. Panduch GA, Visalli MR, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin and erythromycin susceptible and resistant pneumococci to MHR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998; 42: 624-30.
157. Wooton M, Bowker KE, Janowska A, Holt HA, MacGowan AP. Invitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci. J Antimicrob Chemother 1999; 44:445-53.
158. Edelstein PH, Edelstein MA. In-vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999; 43:90-5.
159. Miyashita N, Fukano H, Niki Y, Matsushima T. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 2001; 48:403-5.
160. Pascual AA, Ballesta S, Garcia I, et al. Uptake and intracellular activity of Ketolide HMR 3647 in human phagocytic and non phagocytic cells. Clin Microbiol Infect 2001; 7:65-9.
161. Kadota J, Ishimatsu Y, Iwashita T, et al. Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers. Antimicrob Agents Chemother 2002; 46:917-21.
162. Hagberg L, Carbon C, vanRensburg DJ, et al. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. Respir Med 2003; 97:625-33.
163. Hagberg L, Torres A, VanRensburg DJ, et al. Efficacy and tolerability of once daily telithromycin compared with high-dose amoxicillin in the treatment of community-acquired pneumonia. Infection 2002; 30:378-86.
164. Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once daily oral therapy with telithromycin compared with trovafloxacin in the treatment of community-acquired pneumonia. Int J Clin Pract 2003; 57:377-84.
165. Chen D, McGeer A, de Azevedo J, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341:233-9.
166. Ferraro MJ. The rise of fluoroquinolone resistance: fact or fiction? J Chemother 2002; 14(Suppl 3):31-41.
167. Ho PI, Yung RW, Tsang DN, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001; 48:659-65.
168. Low DL, de Azevedo J, Weiss CA, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002; 46:1295-301.
169. Nagai K, Appelbaum PC, Davies TA, et al. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and eastern European countries. Antimicrob Agents Chemother 2002; 46:371-7.
170. Pankuch GA, Bozdogan B, Nagai K, et al. Incidence, epidemiology and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia. Antimicrob Agents Chemother 2002; 46: 2671-5.
171. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002; 34(Suppl 1):S4-16.
172. Tang P, Green K, McGeer A, et al. Emerging resistance in respiratory tract isolates of Streptococcus pneumoniae (SP) in Canada [abstract L992]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:360.
173. Brueggemann AB, Coffman SL, Rhomberg P, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002; 46:680-8.
174. Resistance of Streptococcus pneumoniae to fluoroquinolones -United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2001; 50:800-4.
175. Sahm DF, Karlowsky JA, Kelly LJ, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 2001; 45:1037-42.
176. Sahm DF, Peterson DE, Critchley IA, Thornsberry C. Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob Agents Chemother 2000; 44: 2521-4.
177. Doern G. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumniae in the United States. Clin Infect Dis 2001; 33:5187-92.
178. Hsueh PR, Teng LJ, Wu TL, et al. Telithromycin-and fluoroquinolone- resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data. Antimicrob Agents Chemother 2003; 47:2145-51.
179. Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal
180. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747-50.
181. Kupronis BA, Richards CL, Whitney CG, and the Active Bacterial Core Surveillance Team. Invasive pneumococcal disease in older adults residing in long term care facilities and in the community. J Amer Ger Society 2003; 51:1520-5.
182. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-4.
183. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with pneumonia. Arch Intern Med (in press).
184. Kahn KL, Rogers WH, Rubenstein LV, et al. Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system. JAMA 1990; 264: 1969-73.
185. McGarvey RN, Harper JJ. Pneumonia mortality reduction and quality improvement in a community based hospital. Quality Rev Bull 1993; 19:124-30.
186. Rosenstein AH, Hanel JB, Martin C. Timing is everything: impact of emergency department care on hospital length of stay. J Clinical Outcomes Management 2000; 7:31-6.
187. Battleman DS, Calahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay with community acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med 2002; 162:682-8.
188. Nuorti JP, Butler JC, Parley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342:681-9.
189. Rodvold, KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997; 41: 1399-402.
190. Tessier, PR, Kim MK, Zhou W, et al. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002; 46:1425-34.
191. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002; 24:736-51.
192. Vergis EN, Indorf A, File TM, Jr, et al. Azithromycin vs. cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter study. Arch Intern Med 2000; 160:1294-300.
193. Frank E, Lin J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community acquired pneumonia. Clin Ther 2002; 24:1292-308.
194. Contopoulos-Ioannidis DG, loannidis JP, Chow P, Lau J. Metaanalysis of randomized controlled trials of the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48:691-703.
195. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159:1835-42.
196. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 2003; 51: 691-6.
197. Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000; 118:1839-40.
198. Brueggeman AB, Phaller MA, Doern GV. Use of penicillin MICs to predict in vitro activity of other β-lactam antimicrobial agents against Streptococcus pneumoniae. J Clin Microbiol 2001; 39:367-9.
199. Aubier M, Verster R, Regamey C, et al. Once-daily sparfloxacin versus high dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis 1998; 26:1312-20.
200. File TJ Jr, Tan JS. International guidelines for treatment of community-acquired pneumonia in adults: the role of macrolides. Drugs 2003; 63:181-205.
201. Fernandez-Sabe N, Carratala J, Dorca J. Efficacy and safety of sequential amoxicillin-clavulanate in the treatment of anaerobic lung infections. Eur J Clin Microbiol Infect Dis 2003; 22:185-7.
202. Roson B, Carratala J, Tuban F, et al. Usefulness of beta-lactam therapy for community-acquired pneumonia in the era of drug resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Microb Drug Resist 2001; 7:85-96.
203. Fogarty CM, Cyganowski M., Palo WA, et al. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther 2002; 24: 1854-70.
204. Van Zyl L, le Roux JG, LaFata JA, et al. Cefditoren pivoxil vs. cefpodoxime proxetil for community-acquired pneumonia: results of a multi-center, prospective, randomized, double blind study. Clin Ther 2002; 24:1840-53.
205. Clark CL, Nagai K, Dewasse BE, et al. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother 2002; 50:33-41.
206. Johnson JR. Doxycycline for treatment of community-acquired pneumonia. Clin Infect Dis 2002; 35:632.
207. Malcolm C, Marrie TJ. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. Arch Intern Med 2003; 163:797-802.
208. White RL, Enzweiler KA, Friedrich LV, Wagner D, Hoban D, Bosso JA. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000. Diag Microbiol Infect Dis 2002; 43:207-17.
209. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9:1-9.
210. Jones RN: Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother 2003; 47:292-6.
211. Gotfried M, Quinn TC, Gothelf S, et al. Oral gatifloxacin in outpatient community-acquired pneumonia: results from Tea CES, a community-based, open-label multicenter study. Diagn Microbiol Infect Dis 2002; 44:85-91.
212. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treating community-acquired pneumonia: JAMA 2000; 283:749-55.
213. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous and oral moxifloxacin compared to sequential IV and oral co-amoxiclav with or without clarithromycin in patients with community acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746-54.
214. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or defuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41:1965-72.
215. Salkind AR, Cuddy PG, Foxworth JW. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother 2002; 36:1938-43.
216. Weiss K, Restieri C, Gauthier R, et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001; 33:517-22.
217. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case control study. Clin Infect Dis 2001; 32:701-7.
218. Klugman KP. The role of clonality in the global spread of fluoroquinolone-resistant bacteria. Clin Infect Dis 2003; 36:783-5.
219. Quale J, Landman D, Ravishankar J, et al. Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg Infect Dis 2002; 8:594-7.
220. Perez-Trallero E, Marimon JM, Gonzalez A, Iglesias L: Spain (14-5) international multiresistant Streptococcus pneumoniae clone resistant to fluoroquinolones and other families of antibiotics. J Antimicrob Chemother 2003; 51:715-9.
221. Levison ME, Mangura CT, Lorber B, et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann Intern Med 1983; 98:466-71.
222. Gudiol F, Manressa F, Pallares R, et al. Clindamycin vs. penicillin for anaerobic lung infections: high rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. Arch Intern Med 1990; 150:2525-9.
223. Muller MP, Low DE, Green KA, et al. Clinical and epidemiologic features of group A streptococcal pneumonia in Ontario Canada. Arch Intern Med 2003; 163:467.
224. McCormick AW, Whitney CG, Farley MM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003; 9:390-2.
225. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-54.
226. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37:230-7.
227. Fuchs PC, Barry AL, Brown SD. In vitro activity of telithromycin against Streptococcus pneumoniae resistant to other antimicrobials including cefotaxime. J Antimicrob Chemother 2002; 49:399-401.
228. Fogarty CM, Kohno S, Kuchanan P, et al. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J Antimicrob Chemother 2003; 51:947-55.
229. Ball P, File TM, Twynholm M, Henkel T. Efficacy and safety of gemifloxacin 320 mg once daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents 2001; 18:19-27.
230. File TM Jr, Schelmmer R, Garau J, et al. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 2001; 48:67-74.
231. Lode H, File TM Jr, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multi-center study of clinical efficacy and tolerability. Clin Ther 2002; 24: 1915-36.
232. Vetter N, Cambroncro-Hernandez E, Rohlf J, et al. A prospective randomized double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002; 24:1770-85.
233. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, et al. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002; 34:1076-83.
234. Moellering RC. Linezolid: the first oxazolidinones antimicrobial. Ann Intern Med 2003; 138:135-42.
235. San Pedro GS, Cammarata SK, Oliphant TH, et al. Linezolid vs. ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002; 34: 720-8.